ERBB2 and breast carcinoma: Among patients with HR‐positive breast cancer, the median age at diagnosis did not differ significantly between HER2‐low and HER2‐0 groups (p = 0.367); however, fewer HER2‐low patients were over the age of 65 (16.4% vs. 18.6%, p = 0.031).